The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.
Rebecca Suk Heist
No relevant relationships to disclose
Leena Gandhi
No relevant relationships to disclose
Geoffrey Shapiro
Research Funding - Merck KGaA
Naiyer A. Rizvi
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Jose Baselga
Consultant or Advisory Role - Merck KGaA
Scott B Yerganian
No relevant relationships to disclose
Karl Hsu
Employment or Leadership Position - Sanofi
Janet Ogden
Employment or Leadership Position - EMD Serono
Loïc Vincent
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Research Funding - Sanofi
Expert Testimony - Sanofi
Oliver von Richter
Employment or Leadership Position - Merck KGaA
Giuseppe Locatelli
Employment or Leadership Position - Merck Serono
Ekatherine Asatiani
Employment or Leadership Position - Merck Serono
Jeffrey R. Infante
No relevant relationships to disclose